BiotechTube
Aqtual

Aqtual

San Francisco, United States· Est.
aqtual.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Aqtual is an early-stage diagnostics company developing a novel platform to extract clinically actionable insights from circulating chromatin and cell-free DNA. Its proprietary biochemistry and data science approach enables the creation of a catalog of disease-specific signatures, with an initial focus on guiding therapy management for rheumatoid arthritis patients. The company is conducting a prospective clinical study to validate its test in a real-world setting, positioning it to address significant unmet needs in precision medicine for chronic inflammatory diseases and oncology.

Inflammatory conditionsOncologyImmunologyCardiovascular diseasesMetabolic diseasesNeurological conditions

Technology Platform

Proprietary platform capturing circulating chromatin from cell-free DNA in blood to measure epigenetics, gene regulation, and transcriptomics, analyzing over 1.6M+ regulatory genomic elements.

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The high cost of managing chronic diseases like RA creates a significant market for tests that can guide therapy and reduce ineffective drug spending.
The platform's ability to generate a multi-omics signature from a simple blood draw could be applied across numerous disease areas, enabling rapid pipeline expansion and partnerships in drug development.

Risk Factors

The core technology is novel and requires extensive clinical validation to prove utility and achieve regulatory approval.
The company is pre-revenue and faces significant competition in the liquid biopsy space, necessitating clear differentiation and substantial capital to reach commercialization.

Competitive Landscape

Aqtual competes in the broad liquid biopsy and multi-omics diagnostics market, which includes large players like Guardant Health, Freenome, and Natera in oncology, and companies like SomaLogic in proteomics. Its specific focus on epigenetics from cfDNA for chronic inflammatory diseases is a differentiating but nascent niche.

More companies in Diagnostics & Precision Medicine →More companies in United States →